With respect to prostate cancer, higher PXR expression in cancerous versus normal tissues has been observed, and PXR activation is associated with increased tumor progression and resistance to the chemotherapeutic drugs [38,39,40]. This evidence concerns the gene NR1I2 and prostate carcinoma.